|
Prescribed non-steroidal anti-inflammatory drugs and centrally acting agents. (*) means that the drug was discontinued at least 24 hrs before the study. Plasma half-life of each compound is also indicated. |
|||||
| Fibromyalgia |
Rheumatoid Arthritis |
||||
|
|
|||||
| Drug |
Number of patients |
Plasma half-life (hours) |
Drug |
Number of patients |
Plasma half-life (hours) |
|
|
|||||
| clonazepam |
6 |
20–60 |
acetaminophen* |
4 |
4–6 |
| acetaminophen* |
5 |
4–6 |
celecoxib* |
3 |
10–12 |
| mianserin |
2 |
21–61 |
diclofenac* |
3 |
3–7 |
| alprazolam |
2 |
12–15 |
piroxicam* |
2 |
34–50 |
| bromazepam |
1 |
20 |
clonazepam |
1 |
20–60 |
| triazolam |
1 |
1.5–5.5 |
alprazolam |
1 |
12–15 |
| piroxicam* |
1 |
34–50 |
indomethacin* |
1 |
4–5 |
| celecoxib* |
1 |
10–12 |
aspirin* |
1 |
2–3 |
| ketoprofen* |
1 |
1.5–4 |
rofecoxib* |
1 |
17 |
| fluoxetine |
1 |
96–144 |
ibuprofen* |
1 |
2–3 |
| gabapentin* |
1 |
5–9 |
gabapentin* |
1 |
5–9 |
Martinez-Lavin et al. BMC Musculoskeletal Disorders 2002 3:2 doi:10.1186/1471-2474-3-2 |
|||||